Through Consolidation Durvalumab, Limited-Stage SCLC Receives a New Standard of Care.

Published Date: 07 Jun 2024

In the durvalumab group, the median OS was 55.9 months, while in the placebo group it was 33.4 months.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Ultrasound imaging of breast cancer tumors offers noninvasive monitoring of treatment effectiveness

2.

Liquid Biopsy for Colorectal Cancer Screening Might Not Be Ready for Prime Time.

3.

MET Inhibitor Increases Osimertinib Activity in EGFR+ Advanced NSCLC

4.

Alone for 500 Days, but Never Lonely: The Introvert's Dream.

5.

The FDA Approves the New Frontline Aggressive ALL Regimen.


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot